GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cotinga Pharmaceuticals Inc (OTCPK:COTQF) » Definitions » Operating Margin %

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Operating Margin % : 0.00% (As of Jan. 2020)


View and export this data going back to 2007. Start your Free Trial

What is Cotinga Pharmaceuticals Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Cotinga Pharmaceuticals's Operating Income for the three months ended in Jan. 2020 was $-0.36 Mil. Cotinga Pharmaceuticals's Revenue for the three months ended in Jan. 2020 was $0.00 Mil. Therefore, Cotinga Pharmaceuticals's Operating Margin % for the quarter that ended in Jan. 2020 was 0.00%.

The historical rank and industry rank for Cotinga Pharmaceuticals's Operating Margin % or its related term are showing as below:


COTQF's Operating Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -156.305
* Ranked among companies with meaningful Operating Margin % only.

Cotinga Pharmaceuticals's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cotinga Pharmaceuticals's Operating Income for the three months ended in Jan. 2020 was $-0.36 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2020 was $-1.81 Mil.


Cotinga Pharmaceuticals Operating Margin % Historical Data

The historical data trend for Cotinga Pharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cotinga Pharmaceuticals Operating Margin % Chart

Cotinga Pharmaceuticals Annual Data
Trend Apr10 Apr11 Apr12 Apr13 Apr14 Apr15 Apr16 Apr17 Apr18 Apr19
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cotinga Pharmaceuticals Quarterly Data
Apr15 Jul15 Oct15 Jan16 Apr16 Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cotinga Pharmaceuticals's Operating Margin %

For the Biotechnology subindustry, Cotinga Pharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cotinga Pharmaceuticals's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cotinga Pharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cotinga Pharmaceuticals's Operating Margin % falls into.



Cotinga Pharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cotinga Pharmaceuticals's Operating Margin % for the fiscal year that ended in Apr. 2019 is calculated as

Operating Margin %=Operating Income (A: Apr. 2019 ) / Revenue (A: Apr. 2019 )
=-2.055 / 0
= %

Cotinga Pharmaceuticals's Operating Margin % for the quarter that ended in Jan. 2020 is calculated as

Operating Margin %=Operating Income (Q: Jan. 2020 ) / Revenue (Q: Jan. 2020 )
=-0.36 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cotinga Pharmaceuticals  (OTCPK:COTQF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cotinga Pharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Cotinga Pharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
82 Richmond Street East, The Canadian Venture Building, Toronto, ON, CAN, M5C1P1
Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up to 30% of all cancers.

Cotinga Pharmaceuticals (Cotinga Pharmaceuticals) Headlines

From GuruFocus

Cotinga Pharmacueticals Announces Closing of Unit Offering

By GlobeNewswire GlobeNewswire 05-22-2019